Sun Pharmaceutical Industries Limited: Psoriasis trials

The registry lists 22 Psoriasis studies with Sun Pharmaceutical Industries Limited as lead sponsor. 0 are open to participants now and 17 have results posted.

Early Phase 1 1Phase 1 2Phase 2 8Phase 3 8Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy and Safety of Tildrakizumab in the Treatment of Scalp PsoriasisCompletedNCT03897088Phase 3Results posted
• A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With PsoriasisCompletedNCT03718299Phase 4Results posted
• Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%TerminatedNCT03212963Phase 4Results posted
• Phase III Clinical Study in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02933866Phase 3Results posted
• Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXSCompletedNCT02933528Phase 2Results posted
• Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical ProductCompletedNCT02933502Phase 2Results posted
• An Open Label, Safety Study to Assess the Potential for Adrenal SuppressionCompletedNCT02932878Phase 2Results posted
• Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp PsoriasisCompletedNCT02932462Phase 3Results posted
• Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque PsoriasisCompletedNCT02618759Phase 3Results posted
• Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque PsoriasisCompletedNCT02601469Phase 2Results posted
• A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical StudyCompletedNCT02413229Phase 2Results posted
• Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque PsoriasisCompletedNCT02340169Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)CompletedNCT01722331Phase 3Results posted
• Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT01206660Phase 3Results posted
• Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque PsoriasisCompletedNCT01206387Phase 3Results posted
• Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis StudyCompletedNCT01043393Phase 2Results posted
• Desoximetasone Spray 0.05%, 0.25%; Dose Ranging StudyCompletedNCT01018134Phase 2Results posted
• A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.CompletedNCT05282771Early Phase 1
• To Evaluate the Therapeutic Equivalence and Safety in Treatment of Scalp PsoriasisCompletedNCT03880357Phase 1
• An Open-Label Study to Assess SafetyCompletedNCT03645499Phase 1
• Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque PsoriasisWithdrawnNCT03298581Phase 2
• A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)WithdrawnNCT01936688Phase 3